Ignacio Melero Bermejo

91PUBLICATIONS
467CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (91)

|Sep 07, 2026
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.

|Aug 25, 2026
CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells.

|Aug 06, 2026
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

|Aug 04, 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

|Jul 20, 2026
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

|Jul 10, 2026
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Pageof 16

Frequent Collaborators

28 joint publications

Pedro Berraondo

15 joint publications

Álvaro Teijeira

13 joint publications

Maite Alvarez

12 joint publications

Iñaki Eguren-Santamaria